Abstract:Objective To investigate the clinical characteristics and diagnostic points of idiopathic type 1 diabetes and its subtypes. Methods Firstly, islet autoantibodies,including glutamic acid decarboxylase antibody (GAD-Ab), protein tyrosine phosphate antibody (IA2-Ab) and insulin autoantibody (IAA),were measured in 144 diabetics with an initial onset of unprovoked ketosis or ketoacidosis. The clinical characteristics, biochemical parameters and HLA-DQ genotypes were compared between patients with (group A,n=60 ) and without autoantibodies (group B, n=84 ). Secondly, according to HLA DQA1-DQB1 haplotypes,group B were further divided into four groups,including S(+)P(-) (group B1, n=16 ), S(-)P(+)(n=10), S(-)P(-)(n=28) and S(+)P(+)(n=3). S(+)P(-) were patients with susceptible HLA DQA1-DQB1 haplotypes and without protective ones. S(-)P(+) were those with protective but without susceptible haplotypes. S(-)P(-) were patients who lack the both and S(+)P(+) were those who have the both. The four groups were compared to find if there was any difference between them. Thirdly, we selected the patients whose body mass index (BMI) <25 kg/m 2 as group B2 (n=23) and those ≥25 kg/m 2 as group B3 (n=15) among patients without susceptible haplotypes [S(-)]. The clinical characteristics were compared between group B2 and group B3, to evaluate if there were any difference between group A and groups B1, B2 and B3. Results Compared with group A, patients in group B owned older age at onset, higher BMI, more obese, less severe DKA, higher level of serum triglyceride and C peptide and more often combined with hypertension. After 2-year follow-up, more patients in group B could achieve acceptable glycemic control or even discontinue insulin therapy. Lower frequency of susceptible HLA DQA1-DQB1 haplotypes and higher frequency of protective ones were found in patients in group B than those in group A. Among patients in four groups, group B1, B2, B3 and group A, patients in group A demonstrated the youngest age at onset, most severe DKA and lowest level of serum C peptide. After 2-year follow-up, no patients could discontinue insulin injection and also obtained glycemic control. On the other hand, patients in group B3 had the oldest age at onset, least severe DKA and highest level of serum C peptide. After 2-year follow-up, more than 70% patients could obtain good glycemic control without insulin. The phenotype of patients in group B2 and B3 were intermediate between group A and group B3. Conclusion There are three key points for diagnosing a patient with idiopathic type 1 diabetes:(1)New-onset (duration less than 6 months) diabetes with unprovoked ketosis or DKA. (2)Islet autoantibodies (GAD-Ab, IA2-Ab, IAA) negative. (3)Excluding diabetes with frank etiology. Idiopathic type 1 diabetes is distinct disease with heterogeneous phenotypes. HLA-DQ genotyping is recommended to determine the subtypes: (1)autoimmune-prone idiopathic type 1 diabetes, (2)typical idiopathic type 1 diabetes, and (3)atypical idiopathic type 1 diabetes. This is helpful to its prognosis judgment and etiological investigation.

Identifying clinical criteria to predict Type 1 diabetes, as defined by absolute insulin deficiency: a systematic review protocol

Approaches to Measuring Beta Cell Reserve and Defining Partial Clinical Remission in Paediatric Type 1 Diabetes

Evaluating optimal utilisation of technology in type 1 diabetes mellitus from a clinical and health economic perspective: protocol for a systematic review

Classification of type 1 diabetes: A pathogenic and treatment-based classification

Subtypes of Type 2 Diabetes Determined From Clinical Parameters

Establishment of Clinical Diagnosis Model of Type 1 Diabetes Mellitus

Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes in Youth Study

Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response

An online tool using clinical factors to estimate the probability of partial clinical remission of adult-onset Type 1 diabetes

Type 1 Diabetes—A Clinical Perspective

Point-of-care testing of HbA1c levels in community settings for people with established diabetes or people at risk of developing type 2 diabetes: a systematic review and meta-analysis protocol

Clinical prediction models combining routine clinical measures identify participants with youth-onset diabetes who maintain insulin secretion in the range associated with type 2 diabetes: The SEARCH for Diabetes in Youth Study

A novel refined classification system for type 2 diabetes in adults: A Chinese retrospective cohort study

Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol

Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment response

Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review

Clinical Characteristics and Primary Classification for Newly Diagnosed Ketosis-Onset Diabetes

Clinical Characteristics and Diagnostic Points of Idiopathic Type 1 Diabetes and Its Subtypes

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes

Hidden hunger in patients with type 2 diabetes (T2D) and its effect on glycaemic control: a protocol for systematic review and meta-analysis